Compare Bristol-Myers Squibb Co (BMY) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Colgate-Palmolive Company — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while Colgate-Palmolive Company trades at $92 (market cap $73.59B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | CL | |
|---|---|---|
Market Cap | $129.94B | $73.59B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $99.14 |
52-Week Low | $42.60 | $74.98 |
Enterprise Value | $163.92B | $80.07B |
Dividend Yield | 3.96% | 2.3% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
